{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:06:13Z","timestamp":1787169973767,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bethune Public Welfare Foundation","award":["Z04J2025E170"],"award-info":[{"award-number":["Z04J2025E170"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50815-5","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:08:38Z","timestamp":1779127718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of toripalimab and bevacizumab versus sorafenib for advanced hepatocellular carcinoma in China"],"prefix":"10.1038","volume":"16","author":[{"given":"Zhiwei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huide","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"50815_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345. https:\/\/doi.org\/10.3322\/caac.21871 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"50815_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"50815_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4, 47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006 (2024).","journal-title":"J. Natl. Cancer Cent."},{"key":"50815_CR4","doi-asserted-by":"publisher","first-page":"1565692","DOI":"10.3389\/fonc.2025.1565692","volume":"15","author":"L Cano","year":"2025","unstructured":"Cano, L., Foucher, F. & Musso, O. Geographic diversity of human liver cancers mirrors global social inequalities. Front. Oncol. 15, 1565692. https:\/\/doi.org\/10.3389\/fonc.2025.1565692 (2025).","journal-title":"Front. Oncol."},{"key":"50815_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay, H. et al. Global, regional and national burden of primary liver cancer by subtype. Eur. J. Cancer. 161, 108\u2013118. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.023 (2022).","journal-title":"Eur. J. Cancer"},{"key":"50815_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10555-023-10084-4","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang, Y. & Deng, B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 42, 629\u2013652. https:\/\/doi.org\/10.1007\/s10555-023-10084-4 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"50815_CR7","doi-asserted-by":"publisher","unstructured":"Chang, Y., Jeong, S. W., Young Jang, J. & Jae Kim, Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int. J. Mol. Sci. 21. https:\/\/doi.org\/10.3390\/ijms21218165 (2020).","DOI":"10.3390\/ijms21218165"},{"key":"50815_CR8","doi-asserted-by":"publisher","first-page":"8774","DOI":"10.3390\/curroncol30100633","volume":"30","author":"M Cerreto","year":"2023","unstructured":"Cerreto, M. et al. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence. Curr. Oncol. 30, 8774\u20138792. https:\/\/doi.org\/10.3390\/curroncol30100633 (2023).","journal-title":"Curr. Oncol."},{"key":"50815_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12672-025-02099-w","volume":"16","author":"Y Liang","year":"2025","unstructured":"Liang, Y. et al. Long-term survival in a patient with ruptured advanced hepatocellular carcinoma treated with nutritional therapy combined with apatinib and camrelizumab: a case report. Discov Oncol. 16, 378. https:\/\/doi.org\/10.1007\/s12672-025-02099-w (2025).","journal-title":"Discov Oncol."},{"key":"50815_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl. J. Med. 382, 1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745 (2020).","journal-title":"N Engl. J. Med."},{"key":"50815_CR11","doi-asserted-by":"publisher","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 1:EVIDoa2100070 (2022). https:\/\/doi.org\/10.1056\/EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070"},{"key":"50815_CR12","doi-asserted-by":"publisher","first-page":"189334","DOI":"10.1016\/j.bbcan.2025.189334","volume":"1880","author":"P Xu","year":"2025","unstructured":"Xu, P., Hong, C., Liu, L. & Xiao, L. PD-1\/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers. Biochim. Biophys. Acta Rev. Cancer. 1880, 189334. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189334 (2025).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"50815_CR13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S2468-1253(25)00059-7","volume":"10","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial. Lancet Gastroenterol. Hepatol. 10, 658\u2013670. https:\/\/doi.org\/10.1016\/S2468-1253(25)00059-7 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"50815_CR14","doi-asserted-by":"publisher","first-page":"1676293","DOI":"10.3389\/fimmu.2025.1676293","volume":"16","author":"Z Li","year":"2025","unstructured":"Li, Z., He, J. & Ma, K. Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China. Front. Immunol. 16, 1676293 (2025).","journal-title":"Front. Immunol."},{"key":"50815_CR15","unstructured":"National Bureau of statistic. (2024). Available at https:\/\/data.stats.gov.cn\/english\/easyquery.htm?cn=C01 (accessed on Feb 20, 2026)."},{"key":"50815_CR16","unstructured":"Liu, G. et al. The China Guidelines for Pharmacoeconomic Evaluation (2020 English Edition) (China Market Publishing Company, 2020)."},{"key":"50815_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2288-11-139","volume":"11","author":"MW Hoyle","year":"2011","unstructured":"Hoyle, M. W. & Henley, W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med. Res. Methodol. 11, 139. https:\/\/doi.org\/10.1186\/1471-2288-11-139 (2011).","journal-title":"BMC Med. Res. Methodol."},{"key":"50815_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40273-013-0123-9","volume":"32","author":"V Diaby","year":"2014","unstructured":"Diaby, V., Adunlin, G. & Montero, A. J. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics 32, 101\u2013108. https:\/\/doi.org\/10.1007\/s40273-013-0123-9 (2014).","journal-title":"Pharmacoeconomics"},{"key":"50815_CR19","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1017\/S0266462325000017","volume":"41","author":"L Wheaton","year":"2025","unstructured":"Wheaton, L. & Bujkiewicz, S. Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology. Int. J. Technol. Assess. Health Care. 41, e11 (2025).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"50815_CR20","doi-asserted-by":"publisher","unstructured":"Ishak, K. J., Kreif, N., Benedict, A. & Muszbek, N. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics 31, 663\u2013665. https:\/\/doi.org\/10.1007\/s40273-013-0064-3 (2013).","DOI":"10.1007\/s40273-013-0064-3"},{"key":"50815_CR21","unstructured":"Central People\u2019s Government of the People\u2019s Republic of China. The State Council Office of the People\u2019s Republic of China held a press conference on the Report on the Nutrition and Chronic Disease Status of Chinese Residents (2020).accessed on Feb 20, (2026). https:\/\/www.gov.cn\/xinwen\/2020-12\/23\/content_5572785.htm"},{"key":"50815_CR22","unstructured":"YaoZH. Drug Pice. (2026). https:\/\/data.yaozh.com\/ (accessed on Feb 20, 2026)."},{"key":"50815_CR23","doi-asserted-by":"publisher","first-page":"1491404","DOI":"10.3389\/fonc.2024.1491404","volume":"14","author":"Z Zhao","year":"2024","unstructured":"Zhao, Z., Jiang, X., Wen, S. & Hao, Y. Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China. Front. Oncol. 14, 1491404. https:\/\/doi.org\/10.3389\/fonc.2024.1491404 (2024).","journal-title":"Front. Oncol."},{"key":"50815_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/cac2.12110","volume":"40","author":"Y Hou","year":"2020","unstructured":"Hou, Y. & Wu, B. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer Commun. (Lond). 40, 743\u2013745. https:\/\/doi.org\/10.1002\/cac2.12110 (2020).","journal-title":"Cancer Commun. (Lond)"},{"key":"50815_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1186\/s12885-023-11255-w","volume":"23","author":"Z Zheng","year":"2023","unstructured":"Zheng, Z., Fang, L. & Cai, H. Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China. BMC Cancer. 23, 823. https:\/\/doi.org\/10.1186\/s12885-023-11255-w (2023).","journal-title":"BMC Cancer"},{"key":"50815_CR26","doi-asserted-by":"publisher","first-page":"175628482413103","DOI":"10.1177\/17562848241310314","volume":"18","author":"H Zou","year":"2025","unstructured":"Zou, H., Lai, Y., Chen, X., Ung, C. & Hu, H. Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma. Th. Adv. Gastroenterol. 18, 17562848241310314. https:\/\/doi.org\/10.1177\/17562848241310314 (2025).","journal-title":"Th. Adv. Gastroenterol."},{"key":"50815_CR27","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1186\/s12913-022-08661-4","volume":"22","author":"T Zhou","year":"2022","unstructured":"Zhou, T. et al. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma. BMC Health Serv. Res. 22, 1367. https:\/\/doi.org\/10.1186\/s12913-022-08661-4 (2022).","journal-title":"BMC Health Serv. Res."},{"key":"50815_CR28","doi-asserted-by":"publisher","first-page":"e079603","DOI":"10.1136\/bmjopen-2023-079603","volume":"14","author":"H Cai","year":"2024","unstructured":"Cai, H., Lin, J., Zhu, H. & Zheng, Z. Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis. BMJ Open. 14, e079603. https:\/\/doi.org\/10.1136\/bmjopen-2023-079603 (2024).","journal-title":"BMJ Open."},{"key":"50815_CR29","doi-asserted-by":"publisher","first-page":"906956","DOI":"10.3389\/fphar.2022.906956","volume":"13","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Front. Pharmacol. 13, 906956. https:\/\/doi.org\/10.3389\/fphar.2022.906956 (2022).","journal-title":"Front. Pharmacol."},{"key":"50815_CR30","doi-asserted-by":"publisher","first-page":"14871","DOI":"10.1002\/cam4.5724","volume":"12","author":"Z Xu","year":"2023","unstructured":"Xu, Z. et al. Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China. Cancer Med. 12, 14871\u201314880. https:\/\/doi.org\/10.1002\/cam4.5724 (2023).","journal-title":"Cancer Med."},{"key":"50815_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 25, 3\u20139 (2022).","journal-title":"Value Health"},{"key":"50815_CR32","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1016\/j.jaip.2021.10.006","volume":"9","author":"M Greenhawt","year":"2021","unstructured":"Greenhawt, M., Oppenheimer, J. & Codispoti, C. D. A Practical Guide to Understanding Cost-Effectiveness Analyses. J. Allergy Clin. Immunol. Pract. 9, 4200\u20134207. https:\/\/doi.org\/10.1016\/j.jaip.2021.10.006 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"50815_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12885-024-11971-x","volume":"24","author":"YB Shim","year":"2024","unstructured":"Shim, Y. B., Oh, B. C., Lee, E. K. & Park, M. H. Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum. BMC Cancer. 24, 189 (2024).","journal-title":"BMC Cancer"},{"key":"50815_CR34","unstructured":"National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013 (2013)."},{"key":"50815_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2165\/00019053-200826090-00002","volume":"26","author":"J Earnshaw","year":"2008","unstructured":"Earnshaw, J. & Lewis, G. NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective. Pharmacoeconomics 26, 725\u2013727 (2008).","journal-title":"Pharmacoeconomics"},{"key":"50815_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","volume":"20","author":"R Cookson","year":"2017","unstructured":"Cookson, R. et al. Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value Health. 20, 206\u2013212. https:\/\/doi.org\/10.1016\/j.jval.2016.11.027 (2017).","journal-title":"Value Health"},{"key":"50815_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10198-021-01364-3","volume":"23","author":"C Kouakou","year":"2022","unstructured":"Kouakou, C. & Poder, T. G. Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression. Eur. J. Health Econ. 23, 277\u2013299. https:\/\/doi.org\/10.1007\/s10198-021-01364-3 (2022).","journal-title":"Eur. J. Health Econ."},{"key":"50815_CR38","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler, H. G., Kong, S. X., Gerth, W. C., Mavros, P. & J\u00f6nsson, B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge. Value Health. 7, 518\u2013528. https:\/\/doi.org\/10.1111\/j.1524-4733.2004.75003.x (2004).","journal-title":"Value Health"},{"key":"50815_CR39","doi-asserted-by":"publisher","first-page":"e0122760","DOI":"10.1371\/journal.pone.0122760","volume":"10","author":"K Nimdet","year":"2015","unstructured":"Nimdet, K., Chaiyakunapruk, N., Vichansavakul, K. & Ngorsuraches, S. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold. PLoS One. 10, e0122760. https:\/\/doi.org\/10.1371\/journal.pone.0122760 (2015).","journal-title":"PLoS One"},{"key":"50815_CR40","doi-asserted-by":"publisher","first-page":"e0297450","DOI":"10.1371\/journal.pone.0297450","volume":"19","author":"A Nu Vu","year":"2024","unstructured":"Nu Vu, A. et al. A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries. PLoS One. 19, e0297450. https:\/\/doi.org\/10.1371\/journal.pone.0297450 (2024).","journal-title":"PLoS One"},{"key":"50815_CR41","doi-asserted-by":"publisher","unstructured":"Tsou, A. Y. et al. and Humanities Committee ajcotAAoN (Ethical Perspectives on Costly Drugs and Health Care: AAN Position Statement. Neurology 97, 685\u2013692. https:\/\/doi.org\/10.1212\/WNL.0000000000012571 (2021).","DOI":"10.1212\/WNL.0000000000012571"},{"key":"50815_CR42","doi-asserted-by":"publisher","first-page":"804237","DOI":"10.3389\/fphar.2021.804237","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls. Front. Pharmacol. 12, 804237. https:\/\/doi.org\/10.3389\/fphar.2021.804237 (2021).","journal-title":"Front. Pharmacol."},{"key":"50815_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.5582\/bst.2019.01339","volume":"13","author":"M Tang","year":"2020","unstructured":"Tang, M., Song, P. & He, J. Progress on drug pricing negotiations in China. Biosci. Trends. 13, 464\u2013468. https:\/\/doi.org\/10.5582\/bst.2019.01339 (2020).","journal-title":"Biosci. Trends"},{"key":"50815_CR44","doi-asserted-by":"publisher","first-page":"942638","DOI":"10.3389\/fpubh.2022.942638","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Yi, H., Fang, K., Bao, Y. & Li, X. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis. Front. Public. Health. 10, 942638. https:\/\/doi.org\/10.3389\/fpubh.2022.942638 (2022).","journal-title":"Front. Public. Health"},{"key":"50815_CR45","doi-asserted-by":"publisher","first-page":"110543","DOI":"10.1016\/j.intimp.2023.110543","volume":"122","author":"Y Shu","year":"2023","unstructured":"Shu, Y., Tang, Y., Ding, Y. & Zhang, Q. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma. Int. Immunopharmacol. 122, 110543. https:\/\/doi.org\/10.1016\/j.intimp.2023.110543 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"50815_CR46","doi-asserted-by":"publisher","first-page":"117955492412993","DOI":"10.1177\/11795549241299393","volume":"18","author":"G Xiang","year":"2024","unstructured":"Xiang, G. et al. First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis. Clin. Med. Insights Oncol. 18, 11795549241299393. https:\/\/doi.org\/10.1177\/11795549241299393 (2024).","journal-title":"Clin. Med. Insights Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50815-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:41:55Z","timestamp":1786452115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50815-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50815"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50815-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a cost-effectiveness analysis based on model construction and does not involve human, so ethical review is not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24928"}}